Statistically Justifiable Visible Residue Limits - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Statistically Justifiable Visible Residue Limits
Current methods for establishing visible residue limits (VRLs) are not statistically justifiable. The author proposes a method for estimating VRLs based on logistic regression.


Pharmaceutical Technology
Volume 34, Issue 3, pp. 58-71

Conclusion

Logistic regression was demonstrated to be a better approach than the current method for estimating accurate and statistically justifiable VRLs based on discrete responses. It has the advantage of always making biologically meaningful predictions and, in most cases, its predictions closely reflect observations. Logistic regression should be used to determine VRLs rather than current method. Because the model may provide a much larger VRL than the current method does, the quality of visual inspection, in terms of the discrete response, can be improved by properly controlling the experimental variables and defining the acceptance criterion for the estimation of VRL.

Based on the modeling procedure, VRL can be defined as a scientifically justifiable residue concentration that, when viewed with the unaided eye, as measured by a specific method, would be detected by the observers with a predefined acceptance criterion. Once established, the VRL could then be used for CV and routine monitoring purposes. It would be appropriate to define the VC criterion as the absence of all particulate and nonparticulate contaminants above the established VRL from the surface when viewed with the unaided eye under preverified viewing conditions.

M. Ovais is a senior pharmaceutical scientist at Xepa-Soul Pattinson, 1-5, Cheng Industrial Estate, 75250 Melaka, Malaysia, tel. +60 63351515, fax +60 63355829,
.

References

1. PIC/S, "Recommendations on Validation Master Plan, Instal-lation and Operational Qualification, Non-Sterile Process Validation, Cleaning Validation," (PIC/S, Geneva, Aug. 2002).

2. PDA Pharmaceutical Cleaning Validation Task Force, PDA J. Pharm. Sci. Technol. 52 (6), 1–23 (1998).

3. W. Hall, J. Val. Technol. 14 (1), 42–49 (2007).

4. R.J. Forsyth, J. Hartman, and V. Van Nostrand, Pharm. Technol. 30 (9), 104–114 (2006).

5. R.J. Forsyth and J. Hartman, Pharm. Eng. 28 (3), 1–10 (2008).

6. European Chemical Industry Council, Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants, (CEFIC, Brussels, Dec. 2000)

7. G.L. Fourman and M.V. Mullen, Pharm. Technol. 17 (4), 54–60 (1993).

8. NASA, "Space Shuttle, Contamination Control Requirements (Lyndon B. Johnson Space Center, Houston, TX)," SN-C-0005, Rev. D, 1–3 (July 20, 1998).

9. D. A. LeBlanc, Pharm. Technol. 22 (10), 136–148 (1998).

10. R.J. Forsyth, V. Van Nostrand, and G. Martin, Pharm. Technol. 28 (10), 58–72 (2004).

11. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (10), 152–161 (2005).

12. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (4), 134–140 (2005).

13. G. Hutcheson and N. Sofroniou, "Logistic Regression," in The Multivariate Social Scientist: Introductory Statistics Using Generalized Linear Models (Sage Publications, London, 1st ed., 1999), pp. 113–152.

14. J.L. Fleiss, B. Levin, and M.C. Paik, "Logistic Regression," in Statistical Methods for Rates and Proportions, W.A. Shewart and S.S. Wilks, Eds. (John Wiley and Sons, Hoboken, NJ, 3rd ed., 2003), pp. 284–339.

15. F.Y. Hsieh, D.A. Bloch, and M.D. Larsen, Stat. Med. 17 (14), 1623–1634 (1998).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here